Targeting mucosal-associated invariant T (MAIT) cells for immunotherapy of HCC

Benjamin Ruf,Matthias Bruhns,Sepideh Babaei,Noémi Kedei,Lichun Ma,Mahler Revsine,Mohamed-Reda Benmebarek,Chi Ma,Bernd Heinrich, Vinutha Subramanyam, Jin Qi,Simon Wabitsch, B. L. Green,Kylynda C. Bauer,Yuta Myojin,Layla T. Greten,Justin D. McCallen,Patrick Huang,Rajiv Trehan, Xiaolin Wang,Amran Nur, Dana Q. M. Soika,Marie Pouzolles,Christine N. Evans,Raj Chari,David E. Kleiner,William G. Telford,Kimia Dadkhah, Allison Ruchinskas,Merrill K. Stovroff, James D. Kang,Kesha Oza,Mathuros Ruchirawat,Alexander Kroemer, X. W. Wang,Manfred Claassen,Firouzeh Korangy,Tim F. Greten

Zeitschrift Fur Gastroenterologie（2023）

引用 0|浏览10

暂无评分

摘要

Introduction The cellular composition of the hepatocellular carcinoma (HCC) tumor microenvironment (TME) has major impact on tumor initiation, progress, and therapy response. Mucosal-associated invariant T (MAIT) are an abundant T cell subtype in the human liver and play a crucial role in regulating immunity and inflammation. Yet, their role in HCC and their potential for cancer immunotherapy remains elusive.

查看译文

关键词

immunotherapy,hcc,cells,mucosal-associated

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要